Drug intelligence / Profile preview

AGX9905

Development stage: Preclinical
Lead developer: CCP
Modality: Small Molecules
Administration: Oral

Overview

AGX9905 is a generic oral liquid drug candidate developed by Agenix Pharmaceuticals. It is part of a portfolio of niche generic products (AGX9901 through AGX9905) intended for submission via the Abbreviated New Drug Application (ANDA) pathway. The specific active pharmaceutical ingredient (API) and therapeutic indication for AGX9905 have not been publicly disclosed by the company. Development activities, including R&D and CDMO coordination, were targeted for completion with an ANDA filing in the 2020-2021 timeframe. Agenix Pharmaceuticals focuses on the development and manufacturing of niche generic oral liquid dosage forms.

Beyond the preview

Go deeper on AGX9905.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGX9905.

Explore the full profile